Globus Medical price target lowered to $66 from $76 at Wells Fargo

Wells Fargo lowered the firm’s price target on Globus Medical (GMED) to $66 from $76 and keeps an Overweight rating on the shares. The firm notes Q2 sales in line with the pre-announcement, but EPS came in 11c ahead of cons. Enabling Tech sales bounced back in Q2, but were still down year-over-year. Wells would have preferred to see better robotic sales growth, but is encouraged by the quarter-to-quarter bounce back.